Medical Prognosis Institute and Aalborg University Hospital, Haematological Department and Aarhus University have initiated a 5-year collaboration to develop improved cancer treatment.

Medical Prognosis Institute (MPI) and Aalborg University Hospital, Haematological Department cross the threshold to a 5-year Research and Development Agreement with the purpose of developing and testing new molecular biology tools for cancer treatment.

"This is a decisive step towards improved cancer treatment. More specifically, MPI has developed a new technology, which, on the basis of a tissue or blood sample can predict which chemo therapy is most effective on a patient by patient basis. The technology is based on DNA-microarrays and MPI's world patent pending Drug Response Predictor, which is an important step towards personalized medicine" says Jesper Drejet, President and CEO of Medical Prognosis Institute.

The novel technology from MPI can be applied to all types of cancer. During first phase, the methods will be tested in lymphoma, leukemia and multiple myeloma - all haematological cancer diseases affecting blood or bone marrow.

"The preliminary results look very promising and will improve our ability to deliver swift and more efficient cancer treatment. However, before the methods can be applied on a routine basis in cancer treatment, they need to be adapted and tested in forward looking clinical trials. The collaboration reflects the Haematological Department's focus on the use of advanced genetic diagnostics in cancer treatment", says Dr. Hans E. Johnsen, professor, and head of the Haematological Department at Aalborg University Hospital.

Dr. Johnsen's extensive expertise in haematological diseases and molecular research has led to the new collaboration between the SEED Capital funded MPI and the governmental institutions of Aalborg and Aarhus.